Welcome to our dedicated page for Avadel Pharmaceu news (Ticker: AVDL), a resource for investors and traders seeking the latest updates and insights on Avadel Pharmaceu stock.
Avadel Pharmaceuticals plc was a commercial-stage biopharmaceutical company focused on sleep medicine before its acquisition by Alkermes plc. Its company updates centered on LUMRYZ, an FDA-approved sodium oxybate extended-release oral suspension for cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy.
Recurring developments included LUMRYZ commercialization, clinical and regulatory disclosures for the REVITALYZ trial in idiopathic hypersomnia, operating and financial results, material agreements, shareholder voting matters, governance items and capital-structure changes tied to its public-company status and completed acquisition.
Alkermes (Nasdaq: ALKS) completed its acquisition of Avadel on Feb. 12, 2026, adding FDA-approved LUMRYZ® and a commercial sleep-medicine organization.
The all-cash deal used ~$775 million in cash and $1.525 billion of term loans, is expected to be accretive in 2026, and adds a phase 1 candidate, valiloxybate.
Avadel Pharmaceuticals (Nasdaq: AVDL) announced that the Irish High Court sanctioned, without modification, the scheme of arrangement under which Alkermes will acquire all issued and to be issued Avadel ordinary shares.
The Scheme is expected to take effect on February 12, 2026, subject to delivery of the Court Order to the Registrar, and February 11, 2026 is expected to be the last Nasdaq trading day for Avadel shares.
Avadel Pharmaceuticals (Nasdaq: AVDL) announced that shareholders approved the proposed acquisition by Alkermes on Jan 12, 2026.
At the Scheme Meeting, 61,861,352 votes (97.41%) were cast for the Scheme, 1,646,857 (2.59%) against, and 160,443 abstained; votes for represented 63.03% of Avadel shares outstanding at the record time. At the EGM, the Scheme Approval Proposal passed with 62,444,065 votes (96.53%) for and 2,247,706 (3.47%) against. The Articles amendment and the non-binding Compensation Proposal were also approved (95.85% and 86.37% for, respectively).
Avadel Pharmaceuticals (Nasdaq: AVDL) announced completion of patient enrollment in REVITALYZ, a Phase 3 randomized withdrawal trial of LUMRYZ (sodium oxybate) extended-release for idiopathic hypersomnia (IH) on Dec 18, 2025.
The trial is double-blind, placebo-controlled and measures the primary endpoint of change in Epworth Sleepiness Scale (ESS) at Week 14. Data are expected in Q2 2026. REVITALYZ includes participants switching from immediate-release oxybates and those not currently taking oxybates. ClinicalTrials.gov identifier: NCT06525077.
Avadel Pharmaceuticals (Nasdaq: AVDL) and Alkermes (Nasdaq: ALKS) announced that, in connection with the previously agreed offer for Avadel, a Rule 15 Proposal was despatched on 5 December 2025.
The Rule 15 Proposal was sent to holders of awards under Avadel’s 2017, 2020 and 2021 equity plans and to participants in the Avadel 2017 Employee Share Purchase Plan in respect of the Proposed Transaction, which is to be implemented by a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014.
The Rule 15 Proposal is available for inspection at https://investors.avadel.com/transaction-overview and https://www.alkermes.com/acquisition; recipients who do not receive the proposal were given an investor relations contact and email.
Avadel Pharmaceuticals (Nasdaq: AVDL) announced that Alkermes will acquire the entire issued and to be issued ordinary share capital of Avadel by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014.
Avadel began mailing a Definitive Proxy Statement to shareholders today, which contains full terms of the Proposed Transaction, required statutory information and notices convening the Scheme Meeting and the related Extraordinary General Meeting (EGM).
The Scheme Meeting is scheduled for 12 January 2026 at 10:00 a.m. Irish time and the EGM for 12 January 2026 at 10:15 a.m. Irish time (or immediately after the Scheme Meeting concludes). Both will be held at Arthur Cox LLP, Ten Earlsfort Terrace, Dublin 2.
Avadel Pharmaceuticals (Nasdaq: AVDL) announced that the Irish High Court has ordered a Scheme Meeting for shareholders to consider a proposed acquisition by Alkermes, under a scheme of arrangement. The Scheme Meeting will be held on 12 January 2026 at 10:00 a.m. Irish time and a related EGM on 12 January 2026 at 10:15 a.m. Irish time (or immediately after the Scheme Meeting). Both meetings will take place at Arthur Cox, Ten Earlsfort Terrace, Dublin 2.
A proxy statement constituting the scheme circular, including full terms of the Proposed Transaction and voter entitlement details, will be mailed to Avadel shareholders on or about 3 December 2025. A further announcement will follow when mailing begins.
Alkermes (Nasdaq: ALKS) agreed to increase its recommended offer to acquire Avadel (Nasdaq: AVDL) to up to $22.50 per share — consisting of $21.00 cash plus one non-transferable contingent value right (CVR) payable up to $1.50 if final FDA approval for LUMRYZ for idiopathic hypersomnia in adults is achieved by the end of 2028.
The Increased Offer values Avadel at up to approximately $2.37 billion. The Amended Agreement was approved by both boards and the transaction remains expected to close in Q1 2026, subject to customary conditions and an extended End Date. J.P. Morgan provided fully committed financing for Alkermes.
Avadel (Nasdaq: AVDL) announced its board has determined an unsolicited proposal from H. Lundbeck A/S constitutes a Company Superior Proposal under Avadel’s transaction agreement with Alkermes.
The Lundbeck Proposal values Avadel at up to $23.00 per share (approx. $2.4 billion), a ~29% premium to the Oct 21, 2025 closing price. The offer is comprised of $21.00 cash at closing plus a non-transferable contingent value right (CVR) for up to $2.00 tied to combined U.S. sales of LUMRYZ and valiloxybate: $1.00 if sales ≥ $450M by Dec 31, 2027 and $1.00 if sales ≥ $700M by Dec 31, 2030.
The Alkermes Transaction Agreement remains in effect; a five-business-day matching period may follow and any offer would be subject to shareholder and regulatory approvals.
Avadel (Nasdaq: AVDL) said it received an unsolicited proposal from H. Lundbeck A/S to acquire Avadel for up to $23.00 per share—$21.00 cash at closing plus a non-transferable CVR worth up to $2.00 tied to U.S. net sales milestones for LUMRYZ and valiloxybate by 2027 and 2030. Avadel noted the Lundbeck Proposal is subject to shareholder and regulatory approvals and closing conditions.
The Avadel Board determined in good faith the Lundbeck Proposal would reasonably be expected to result in a Company Superior Proposal under its agreement with Alkermes, permitting discussions but not terminating the Alkermes transaction (up to $20.00 per share).